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Background: Healthcare systems are under increasing strain, predominantly due to chronic 
non-communicable diseases. Connected healthcare technologies are becoming ever more capable 
and their components cheaper. These innovations could facilitate both self-management and 
more efficient use of healthcare resources for common respiratory diseases such as asthma and 
chronic obstructive pulmonary disease. However, newer technologies can only facilitate major 
changes in practice, and cannot accomplish them in isolation.
Focus of review: There are now large numbers of devices and software offerings available. 
However, the potential of such technologies is not being realised due to limited engagement 
with the public, clinicians and providers, and a relative paucity of evidence describing elements 
of best practice in this complex and evolving environment. Indeed, there are clear examples of 
wasted resources and potential harm. We therefore call on interested parties to work collabora-
tively to begin to realize the potential benefits and reduce the risks of connected technologies 
through change in practice. We highlight key areas where such partnership can facilitate the 
effective and safe use of technology in chronic respiratory care: developing data standards and 
fostering inter-operability, making collaborative testing facilities available at scale for small to 
medium enterprises, developing and promoting new adaptive trial designs, developing robust 
health economic models, agreeing expedited approval pathways, and detailed planning of dis-
semination to use.
Conclusion: The increasing capability and availability of connected technologies in respira-
tory care offers great opportunities and significant risks. A co-ordinated collaborative approach 
is needed to realize these benefits at scale. Using newer technologies to revolutionize practice 
relies on widespread engagement and cannot be delivered by a minority of interested specialists. 
Failure to engage risks a costly and inefficient chapter in respiratory care.
Keywords: apps, smart inhaler, connected devices, remote monitoring, co-creation, standards, 
guidelines, health economics
Introduction
The traditional model of face-to-face healthcare delivery is becoming increasingly 
unsustainable as demand continues to increase.1 The introduction of new technologies 
has addressed demand and efficiency issues in other industries, and may permit cost-
effective solutions to healthcare needs. Chronic respiratory disease is a prototypical 
example of chronic care in which technology-mediated care might improve outcomes 
within a manageable cost framework. The potential of novel connected technologies 
must be considered in the context of the challenges associated with implementation at 
a large enough scale to provide sustainable solutions. In this article, we briefly review 
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the types and promise of available solutions and then focus on 
solutions to overcome barriers and facilitate implementation.
Healthcare systems under strain
The need for new models of working
Healthcare systems are under growing pressure from an aging 
and increasingly multimorbid population.2 Not only is the 
number of patients rising but so too is the complexity of pre-
sentations and the array of specialist tests and interventions 
tailored available to address individual patient needs. The 
combination of these factors has led to a growing resource 
crisis over the past decade. The Royal College of Physicians’ 
Future Hospital Commission Report3 observes that had the 
change in health system demands taken place over the period 
of a year, it would have been deemed a “national disaster” 
prompting a suitable response. Yet the fact it has “crept up” 
has resulted in a distinct lack of direct action.
Different healthcare systems face different pressures. 
In lower income countries, there are growing populations 
and a scarcity of resources and trained healthcare staff.4 In 
higher income countries, there is a growing awareness that 
overuse of tests and investigations is wasteful and potentially 
harmful,5 leading to initiatives such as the Choose Wisely 
Campaign.6 It is evident that usual models of face-to-face 
patient–physician consultation in out-patient or community 
settings will become increasingly stretched and unable to pro-
vide safe and timely care. New ways of working are required 
to allow clinicians to support effective self-management at 
scale. This will require remote data capture in a way that 
enables their subsequent incorporation into existing clinical 
records, controls for the limitations of self-report, and cap-
tures the influence of external environmental and seasonal 
influences on disease state. This would allow reliable bench-
marking against care patterns and thus integration of patient 
stratification algorithms into intelligent Clinical Decision 
Support Systems (CDSS).
Chronic respiratory disease as a 
prototype for technology-supported 
management
Over 500 million people worldwide have chronic airways 
disease, with many millions more experiencing common 
conditions such as sleep disordered breathing and pulmonary 
fibrosis.7 Individuals with chronic lung diseases also have a 
higher prevalence of chronic comorbidities related to their 
conditions and related treatments such as cardiovascular 
disease, diabetes, obesity, osteoporosis and depression.8 
Engaging with people who have a respiratory diagnosis 
can, therefore, also present an opportunity for positive inter-
ventions in these areas. Thus, respiratory medicine is well 
positioned as a conduit for new ways of working that focus 
on supporting shared care and self-management through 
improvements in remote assessment and monitoring.
The concept: what can new 
technologies offer?
Monitoring diseases, behavior and their 
context
The past decade has seen a steep change in areas of technol-
ogy relevant to healthcare. Sensors related to physiological 
measurement have become smaller, cheaper, more capable 
and more accurate.9,10 This provides the possibility of remote 
assessment and monitoring of health and disease.11 Tools 
such as electronic peak flow meters can provide standardized 
time-stamped information that can inform clinical decision-
making.12 Devices are not only becoming evermore capable 
and flexible, but also increasingly affordable, ubiquitous 
and interconnected. There are exciting possibilities to gather 
data from a user’s daily activities to contextualize and enrich 
monitoring data. This may be through existing devices such as 
activity monitors, or by adding sensors to items the individual 
uses daily such as an inhaler. Moving toward the “Internet of 
Things” has the potential to reduce issues with stand-alone 
telehealth systems that require dedicated time for interac-
tions using operating systems unfamiliar to the user.13,14 The 
large volume of data recorded by sensors in mobile devices 
can be stored and analyzed close to the point of capture, and 
can be combined with other information in the cloud such 
as atmospheric, pollen count or pollution data (Figure 1).
Intervention based on novel data
Remote monitoring connected to the patient’s own phone 
or computer offers more opportunities to promote behav-
ioral change. Repeated, in-context feedback prompted by 
modest amounts of specific information may support more 
sustained improvements than an annual review based on a 
large volume of (often historic) information. For example, 
results of a measure of interest (e.g., taking inhalers regu-
larly) can be fed back to the user and compared against a 
personal history and target standards, and linked to specific 
adherence interventions, such as daily reminders for missed 
doses, visual feedback of monthly performance, or advice 
by a healthcare professional. This simple feedback of current 
behavior is only one aspect of an ideal, carefully-designed, 
integrated system of assessment and intervention. Such a 
system could address a range of specific patient behaviors: 
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supporting self-regulatory capacity and skills, encouraging 
adjuvant activities, and providing information that empha-
sises opportunities and choice.15
Yet it is not only patient behavior that may be altered 
in this way; new monitoring technologies offer a major 
opportunity to shape and guide clinicians and their practice 
behaviors. Moreover, the availability of multimodal remote 
assessment could increase the confidence of clinicians in 
undertaking “n of 1” trials of treatment, a valuable asset in 
heterogeneous conditions such as asthma.16 As newer tech-
nologies become widely adopted, data from remote sensors 
will be incorporated into decision support tools, including 
risk prediction models. This could permit faster and more 
consistent clinical review, particularly if care is fragmented 
across several providers.
Current state of remote monitoring 
and assessment
There is evidently great potential in the use of remote moni-
toring and connected technologies for chronic respiratory 
conditions. At the time of writing, two main types of tech-
nology are being offered to attempt to realize some of this 
potential: mobile phone application and connected devices. 
Mobile phone applications
Recent reports estimate there are over 150,000 apps, devel-
oped by thousands of companies and individuals.17 The 
majority of these are in English, but the Chinese and other 
global markets are rapidly expanding.18 The number of apps 
available suggests individuals are willing to engage with 
this platform for education or support (Figure 2). A recent 
American study found that more than half of smartphone 
users had downloaded a health-related app and placed high 
levels of trust in their accuracy.19 This enthusiasm appears 
to extend to respiratory disease as over 90% of adolescents 
using personal asthma action plans based on a mobile device 
reported they felt better able to manage their asthma.20
However, the large and increasing number of apps avail-
able also suggests that, despite consumer and developer 
enthusiasm, there are few offerings that fulfill their remit 
and are widely and persistently used.21 This may reflect the 
lack of clinical benefit from stand-alone software: a large 
UK-based randomized controlled trial of a mobile phone 
app for asthma monitoring demonstrated no clinical benefit, 
but added expense.22
From the clinical perspective, mobile applications herald 
the potential to support clinicians’ decision-making by (for 
example) facilitating multifactorial risk assessment calcu-
lations23 or assisting in attitudinal profiling.24 It remains 
uncertain how much value is added by the delivery through a 
mobile device beyond other interfaces that may be less costly.
Connected devices
Low-cost electronics integrated with standard equipment now 
permit the collection and combination of routine data such as 
weight and peak expiratory flow. Similar technology allows 
the monitoring of medication administration such as that used 
in so-called smart inhalers, now a well-established research 
tool25–27 beginning to see targeted use in clinical settings.28
Ingestible technologies also show promise for oral medi-
cation.29 Tools such as pulse oximeters and activity monitors 
that were confined to in-patient or specialist use are now 
routine consumer products30 and could be incorporated into 
smartphones.31 As the data from these monitors can now be 
collected into existing platforms, such as Apple Health, the 
Figure 1 Sources of health and contextualising data other than disease-specific 
apps or devices.
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Figure 2 Number of available mobile phone applications for asthma.
Note: Data from Burbank et al and Wu et al.21,57
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development burden on small to medium enterprises (SMEs) 
is potentially reduced and the market is likely to become 
increasingly congested.32
As with mobile apps, connected devices often secure 
initial engagement but their long-term clinical benefit 
is less clear. Although devices such as smart inhalers 
provide accurate data,33 they have not yet been studied as 
part of a holistic behavioral change system. Small stud-
ies of the isolated introduction of smart inhalers have not 
shown an increase in medication adherence or symptom 
improvement.34
Technologies as a potential hazard
Primum non nocere
New ways of working are always accompanied by new 
challenges and risks. Historically, most medical innovations 
and technologies have been developed to rigorously-defined 
safety standards. Emerging technologies such as apps and 
smart devices, however, are made available directly to con-
sumers, seldom with peer-reviewed publications describ-
ing their scientific rationale or reported effectiveness. The 
absence of the usual levels of protection afforded to patients’ 
risks lower quality standards, such as software that contain 
errors in advice or miscalculated peak flow measurements, 
reaching the patient unimpeded.21 The combination of poten-
tially inaccurate measurement and algorithmic misinterpre-
tation is a concern in this large and growing market. The 
QRISK® cardiovascular risk assessment tool, for example, 
is integral to many thousands of healthcare interactions 
in UK primary care practice. Yet it was found to contain 
a calculation error that could erroneously recommend the 
commencement of statin therapy, resulting in a suspension 
of its use in 2015.35
The rapid evolution of information technologies requires 
intelligent synthesis of vast amounts of data and expert opin-
ion and presentation in a readily accessible format if it is to 
be meaningfully used. The generation and curation of mass 
amounts of data often outpaces data visualization capabilities 
and infrastructure and can raise challenging ethical dilem-
mas. Devices such as continuous positive airway pressure 
(CPAP) machines are now able to transfer data directly to 
providers,36 and mechanisms are being rolled out to permit 
patients to upload information directly into their primary 
care records.37 It is unclear if patients believe the data stream 
from their device is being continuously monitored, and (if 
so) what the implications of this understanding might be 
on the personal level of responsibility patients assume for 
their wellbeing.
Data security
The practice of medicine is predicated on confidentiality 
between clinician and patient. In recent years, however, 
connected technologies to manage chronic conditions or 
promote healthy living have raised new issues in patient 
confidentiality. Recognition of the potential use of video 
communication platforms such as Skype,38–40 for example, has 
led to the suggestion that it may sometimes be in a patient’s 
best interest to trade off absolute data security against the 
value of receiving a remote specialist opinion: “better cured 
than secured.” In the context of smart phones and connected 
devices as self-management supports, connectivity results in 
a convergence of commercial, clinical and research perspec-
tives on data management and confidentiality.
In addition to breaches of confidentiality at the individual 
patient level, cyber-attacks against healthcare providers are 
increasingly becoming common and the industry is lag-
ging behind others in its capability to secure vital data.41 It 
seems unlikely that app and device providers will be able to 
ensure data security in the face of evermore sophisticated 
cyber-attacks. Such data breaches may have serious conse-
quences for individuals, particularly if sensitive incidental 
data is captured or individual devices can be remotely 
manipulated.42 Also of concern, at a population level, is the 
increasing commercialization of healthcare data by providers. 
Healthcare records are sold en masse to industry and users of 
health-related apps and websites and used to inform targeted 
advertising. Data on visits to UK National Health Service 
webpages, for example, is now being shared with Amazon.43
In the preceding sections, we have described the potential 
and increasing availability of connected technologies and 
targeted software. We have also highlighted the relative lack 
of study data supporting their routine clinical use, and the 
potential risks of uncontrolled implementation. The respi-
ratory community therefore faces a major challenge and 
intervention is required to understand why technology-based 
solutions are not fulfilling their potential so that the relevant 
issues can be appropriately addressed.
Why might technology based 
solutions not fulfil their potential?
Economics
Medical apps are usually created by small enterprises and 
offered free or at minimal cost (on average <£1).44 At such low 
levels of return, there is little capacity or incentive for invest-
ment in research and development to deliver high-quality 
medical products, certainly in comparison to the activity of 
pharmaceutical companies. This issue is compounded by the 
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rate of change in operating systems and hardware platforms: 
there is a race to deliver apps to market before they are no 
longer technically functional. In contrast, the approvals 
process for medical interventions is lengthy and technical. 
Developers receive relatively little return on investment and, 
as they are not usually healthcare providers, do not stand 
to gain from the health benefits their app may afford. An 
important step toward future technologies potentially having 
greater clinical value and longevity would therefore appear 
to be co-production with providers. This concept might focus 
efforts on interventions where there is a clinical and financial 
step-change, such as reducing hospital admissions or the use 
of high-cost drugs. Co-production would also ensure both 
parties have a clear understanding of the financial implica-
tions of deploying a new technology beyond the unit cost 
(personnel training, infrastructure, etc.). Involving payers in 
co-production may also reduce the drive for desire- rather 
than need-led content development (Figure 3).
Utility
A notable aspect of many apps and connected devices is the 
lack of clarity in their specific purpose. As with any medical 
intervention, the likelihood of efficacy is dependent on defin-
ing a target population, a specific intervention, and a primary 
outcome. The all-encompassing approach of most apps may 
be influenced by a relative lack of understanding of respira-
tory diseases, or market forces pushing developers to seek 
the largest potential market. Most apps are not developed in 
consultation with experts or patients.45,46 It is apparent that 
co-production with end users could help focus development 
on relevant and tractable clinical and behavioral or activation 
problems. This may begin to address the current “solution 
first” issue of new technologies being brought to market 
without first establishing they are appropriately addressing 
a meaningful issue.47 Co-production between clinicians and 
patients (as previously discussed) could reduce the focus on 
technical capability and focus instead on utility and data that 
can be successfully and meaningfully curated.
Demonstrating effectiveness, even of well-designed tech-
nologies, may also be a challenge, especially if it is aimed 
at hard-to-reach individuals who do not usually engage with 
health services. A randomized controlled trial of mobile 
phone-based self-monitoring for adolescents with asthma 
recruited only 2.4% of those invited.22 This lack of engage-
ment may also reflect a gap in perceived quality between 
the health-related technology on offer and other consumer 
technologies.
The rush to market to capitalize on evolving functional-
ity and avoid obsolescence inevitably limits the time spent 
incorporating ergonomic principles48 into the design of 
technologies or consulting with potential end-users before 
being launched. This is particularly true for SMEs that lack 
institutional memory. Resultant offerings may have shortcom-
ings in their high demand for data entry, suboptimal interface, 
limited functionality, and information provision49 that limit 
user engagement. In the longer term, these issues may be par-
tially overcome through applying new software behind com-
mon social media platforms such as Facebook or intelligent 
assistants such as Siri. However, co-production with patients 
will remain an essential component of successful software 
or device design. Engagement with patient organizations and 
charities will facilitate the design and testing process,50 as will 
developers leveraging learning from other projects such as 
the large European Union-funded collaborative study MyAir-
Coach (http://www.myaircoach.eu/myaircoach/). A further 
challenge in achieving true functional effectiveness will be 
the routine integration and interoperability of the device and/
or the data collected within the patient electronic healthcare 
record51 and within integrated healthcare pathways.52
Creating an environment conducive 
to development and deployment
Current standards
Although regulators classify apps or devices that record data 
on health or disease, those that stop short of suggesting an 
alteration or that essentially digitize previously paper-based 
data forms are largely classified as “non-medical”. As a result, 
there is widespread use of unregulated connected devices 
and apps with the potential to influence health behaviors 
and limited high-quality independent information available 
to guide users in navigating the options available to them. 
Furthermore, as noted, the great majority of these offerings 
have not been robustly developed or tested. Not only does 
Technical
capability
Commerical
demand User need
Not profitable but helpfulProfitable but unhelpful
Potentially profitable and helpful but not yet possible
Figure 3 Technology-based solutions can be considered in terms of current 
technical capability, clinical requirement, and commercial demand.
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this mean individual apps or devices are often flawed in terms 
of their basic functionality, but it is also unclear if their use 
is associated with any benefit.53 The lack of generalizable 
knowledge from robust research studies is further hampering 
the iterative improvement of technology-supported manage-
ment. Developers and clinicians must attempt to keep abreast 
of scanty information scattered across journal articles, web-
pages, white papers, and reports.
In response to this broad issue, many standards, checklists, 
and guidelines have been produced on the implementation of 
e-health, and there is now an e-health aspect to most recom-
mendations for complex interventions. The World Health 
Organization mHealth Technical Evidence Review Group has 
also developed a checklist for mHealth Evidence Reporting 
and Assessment (mERA)54 (Table 1). The mERA document 
is welcome, but does highlight two key limitations common 
to such recommendations. Although it provides a solid basis 
for assessing reports of studies of technology supported 
care, it gives little attention to the specifics of intervention 
development: there is a mention of “user feedback” but no 
Table 1 World Health Organization mERA reporting checklist for respiratory studies
Criteria Item 
no
Notes
Infrastructure (population level) 1 Clearly presents the availability of infrastructure to support technology operations in the study location. 
This refers to physical infrastructure such as electricity, access to power, connectivity etc. in the local 
context. Reporting X% network coverage rate in the country is insufficient if the study is not being 
conducted at the country level
Technology platform 2 Describes and provides justification for the technology architecture. This includes a description of 
software and hardware and details of any modifications made to publicly available software
Interoperability/ HIS context 3 Describes how mHealth intervention can integrate into existing health information systems. Refers to 
whether the potential of technical and structural integration into existing HIS or program has been 
described, irrespective of whether such integration has been achieved by the existing system
Intervention delivery 4 The delivery of the mHealth intervention is clearly described. This should include frequency of mobile 
communication, mode of delivery of intervention (that is, SMS, face-to-face, interactive voice response), 
timing and duration over which delivery occurred
Intervention content 5 Details of the content of the intervention are described. Source and any modifications of the 
intervention content is described
Usability/content testing 6 Describe formative research and/or content and/or usability testing with target group(s) clearly 
identified, as appropriate
User feedback 7 Describes user feedback about the intervention or user satisfaction with the intervention. User feedback 
could include user opinions about content or user interface, their perceptions about usability, access, 
connectivity, etc
Access of individual participants 8 Mentions barriers or facilitators to the adoption of the intervention among study participants. Relates to 
individual-level structural, economic and social barriers or facilitators to access such as affordability, and 
other factors that may limit a user’s ability to adopt the intervention
Cost assessment 9 Presents basic costs assessment of the mHealth intervention from varying perspectives. This criteria 
broadly refers to the reporting of some cost considerations for the mHealth intervention in lieu of a full 
economic analysis. If a formal economic evaluation has been undertaken, it should be mentioned with 
appropriate references. Separate reporting criteria are available to guide economic reporting
Adoption inputs/program entry 10 Describes how people are informed about the program, including training, if relevant. Includes 
description of promotional activities and/or training required to implement the mHealth solution among 
the user population of interest
Limitations for delivery at scale 11 Clearly presents mHealth solution limitations for delivery at scale
Contextual adaptability 12 Describes the adaptation, or not, of the solution to a different language, different population or context. 
Any tailoring or modification of the intervention that resulted from pilot testing/usability assessment is 
described
Replicability 13 Detailed intervention to support replicability. Clearly presents the source code/screenshots/flowcharts 
of the algorithms or examples of messages to support replicability of the mHealth solution in another 
setting
Data security 14 Describes the data security procedures/confidentiality protocols
Compliance with national 
guidelines or regulatory statutes
15 Mechanism used to assure that content or other guidance/information provided by the intervention is in 
alignment with existing national/regulatory guidelines and is described
Fidelity of the intervention 16 Was the intervention delivered as planned? Describe the strategies employed to assess the fidelity of 
the intervention. This may include assessment of participant engagement, use of backend data to track 
message delivery and other technological challenges in the delivery of the intervention
Abbreviations: HIS, health information systems; mERA, mHealth Evidence Reporting and Assessment.
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details of co-development with clinicians, payers or patients. 
There is also little practical guidance for innovators on how 
the evidence requested might be generated.
Practical steps to widespread deployment
Respiratory clinicians and healthcare providers should be 
wary of deploying any technology-based solution that is 
not supported by a peer-reviewed publication that complies 
with the mERA reporting guidance or any subsequently 
developed respiratory-specific iteration of this. However, as 
a community, it is essential that careful thought is given to 
the pragmatic question of how robust evidence for a device 
or software can be delivered and disseminated before the 
technology becomes outdated and/or loses its commercial 
advantage.
We propose that eight core areas of activity would help 
facilitate the development of needed solutions, assess their 
effectiveness and support their implementation in an engaged 
community of people with respiratory disease and the clini-
cians with whom they interact (summarized in Box 1).
Research
Establish research centers
SMEs do not have the budget to undertake clinical studies 
in the same manner as major pharmaceutical companies. 
Establishing innovative testing facilities for connected tech-
nologies could enable innovators to access relevant protocols, 
experts and patient groups in a timely and cost-effective 
manner. This will require initial investment from healthcare 
providers or research funders but will improve co-production, 
research volume and quality. Asthma UK’s AsthmaLab is an 
example of a charitable organization piloting a co-creation 
approach to digital health solutions focused on asthma. This 
type of approach explores how to harness the willingness of 
both people with asthma and asthma-interested clinicians 
to volunteer to develop robust, agile, cost effective testing. 
Centers with a focus on research in this area can also act as 
hubs from which to disseminate results, highlighting how 
newer technologies can provide opportunities to improve 
respiratory care.
Synthesize and simplify guidance
The amount of information on common respiratory 
conditions, behavior change, intervention development, 
implementation science, and medical research methods is 
overwhelming to non-specialists. Parsimonious disease-
specific guidelines for developing technology-mediated 
management solutions for common conditions, disseminated 
in a user-friendly format to current and potential developers 
would be of significant benefit. These guidelines, developed 
in collaboration with all stakeholders, could also provide 
background financial information to support the movement 
toward mature health economic models for new technologies. 
When choosing an app or device, end-users could simply 
check the relevant guidelines had been adhered to in order 
to facilitate and improve their decision-making.
Use adaptive study designs
There is a growing recognition of the need to adopt newer, 
more flexible and responsive trial designs to address clini-
cal management questions in current practice.55 The use of 
adaptive designs and umbrella trials will better facilitate the 
Box 1 Facilitatory conditions for the widespread deployment of technology supported respiratory management
Research
Establish research 
centres
Synthesise & simplify 
guidance
Use adaptive study 
designs
Consider economics of 
technology deployment
Availability
Expedite approval
Develop solutions for 
inter -operability
Dissemination 
to use
Build a central solution 
showroom
Provide clear 
indications and 
instructions for use
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evaluation of multiple solutions with fewer restrictions on 
other aspects of care. New trial designs can also be used to 
understand highly contextualized behavior in subgroups. 
Methodologists and researchers could promote the use of 
such methods by developing practical guides and highlight-
ing best practice examples. The increased efficiency of newer 
study designs may also reassure participants that they are far 
less likely to face relatively long-term allocation to a study 
arm that uses an unhelpful or outmoded technology.
Consider the economics of technology 
deployment
Our understanding of how best to deploy new technologies 
lags behind the technical development. Research is required 
to investigate the optimal method of incorporating new data 
streams into CDSS and, crucially, into the health economics 
around deployment. It is unclear which technologies represent 
good value when costs of training staff, educating patients, 
improving technical infrastructure and managing plentiful data 
are taken into consideration: only when more mature health 
economic models are available will there be a clear picture 
of the role of connected devices going forward. This would 
require close collaboration between health providers and health 
economists to develop and promote the use of such models. The 
potential cost and time efficiencies of using newer technologies 
should motivate clinicians to seek out such collaborations.
Availability
Expedite approval
Regulators such as the US Food and Drug Administration 
and the UK’s Medicines Healthcare Products Regulatory 
Authority have developed clear guidance explaining which 
innovations should be subject to their approval system. How-
ever, developers are still reluctant to pursue approval as they 
perceive the process to be time-consuming and complex. 
We urge regulators to continue to engage with healthcare 
providers and developers to ensure approvals can be made 
in a timely fashion, potentially with the introduction of new, 
proportionate pathways.
Develop solutions for inter-operability
To leverage the potential of newer technologies fully, it will 
be essential to share data between sensors, mobile devices, 
and patient records. A good deal of work is still to be done 
to agree standards for routinely collected data, with the con-
cern that we may end up with multiple unconnected devices 
and pieces of software. These would then rely on manual 
review and repetitive information transfer (with the risk that 
historic data could be lost) and the additional cost of users 
repeatedly needing to learn new interfaces. Solutions for 
inter-operability need urgent consideration by technology 
specialists. These specialists should find other stakeholders 
such as health providers and motivate end-users (clinicians, 
patients) to contribute to these discussions as they seek to 
avoid time-consuming and frustrating incompatibility issues.
Dissemination to use
Build a central solution showroom 
It is insufficient to develop and approve innovative solutions 
without a clear framework for their dissemination to intended 
end-users in an accessible and engaging manner. There have 
been some initiatives to create such an offering (e.g., the Health 
Tools Library56), but we currently lack a system whereby a per-
son with a chronic respiratory condition or a nurse in primary 
care could easily identify and access a high-quality product 
suitable for them. Such an initiative would have a short-term 
benefit for health providers, professionals and people with 
respiratory disease, so should attract their engagement in devel-
opment, alongside patient organizations. Using a showroom 
to highlight potential benefits and to make it easier to access 
technology based solutions improves the likelihood of time-
pressured or more sceptical end-users trying new approaches.
Provide clear indications and instructions 
for use
Medical interventions proven effective in research studies 
should be used in a manner that is consistent with those stud-
ies. In usual practice, decisions are informed by guidelines 
and appropriate prescribing is safeguarded by pharmacists. 
In contrast, new technologies are less likely to feature by 
name in guidelines given their relative rate of revision, and 
there will be less oversight of delivery to patients. Learned 
institutions and healthcare providers will therefore need 
to produce clear general guidance on the practicalities of 
implementation, and invest in training staff on applying this 
guidance in routine care. Individual products require a stan-
dardized summary of characteristics provided by developers 
in line with this guidance to facilitate their rapid integration 
in routine care. Clinicians delivering respiratory care will 
have more confidence in recommending new technologies to 
patients with this familiar style of infrastructure, increasing 
their experience and engagement in this developing area. 
Conclusion
The increasing demand on healthcare services consequent to 
increasing prevalence of chronic diseases cannot be addressed 
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using traditional working practices. The large-scale deploy-
ment of newer connected technologies has the potential 
to empower self-management in respiratory diseases and 
facilitate expert review. However, this would require major 
changes in the way respiratory diseases are currently man-
aged. These changes can only be realised through diverse 
collaborative efforts in research and clinical care, not left to 
the technology-interested minority. To achieve the required 
goals, innovative products must be developed in partnership 
with patients, clinicians, and providers. These products must 
be robustly tested and approved using newer approaches, but 
they must also be readily accessed and used.
We believe that we are at a tipping point in the manage-
ment of chronic respiratory disease. Unless all parties work 
collaboratively to realize the potential benefits, the thousands 
of flowers of innovation that are beginning to bloom will die in 
the absence of facilitatory conditions, accepted development 
quality standards, robust verification of utility, and ready 
access for end-users. If this does not occur, technologies will 
remain a confusing and expensive distraction at a time when 
resources are increasingly stretched.
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